Diagnostic Strategies for Prostate Cancer

  title={Diagnostic Strategies for Prostate Cancer},
  author={B. Djavan and A. Kazzazi and Lori M. Dulabon and M. Margreiter and A. Farr and Markus Johannes Handl and H. Lepor},
  journal={European Urology Supplements},
  • B. Djavan, A. Kazzazi, +4 authors H. Lepor
  • Published 2011
  • Medicine
  • European Urology Supplements
  • Abstract Context Prostate cancer (PCa)is the most common malignancy in men in westernized cultures and the incidence of PCa is rapidly rising in low-risk countries due to significant westernization in these populations. Prostate-specific antigen (PSA) is the gold standard for screening of PCa. Means to improve the specificity and sensitivity of this screening method are imperative. Objective In this article, we review novel blood-, urine-, and tissue-based biomarkers for screening and early… CONTINUE READING
    11 Citations
    Analysis of urinary PSA glycosylation is not indicative of high-risk prostate cancer.
    • 6
    Role of Wnt5a in Prostate Cancer
    • PDF
    Real-time source tracking for quality assurance in HDR prostate brachytherapy
    • 2
    • Highly Influenced


    A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer.
    • 203
    Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
    • 29
    Urine biomarkers in prostate cancer
    • 95
    PSA and Beyond: The Past, Present, and Future of Investigative Biomarkers for Prostate Cancer
    • 76
    • PDF
    Diagnostic biomarkers of prostate cancer
    • 11
    Mortality results from a randomized prostate-cancer screening trial.
    • 2,622
    • Highly Influential
    • PDF